Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
EssilorLuxottica and Diesel announce a ten-year licensing agreement
ESSILORLUXOTTICA AND DIESEL ANNOUNCE A TEN-YEAR LICENSING AGREEMENT Charenton-le-Pont, France and Milan, Italy (18 June 2024)– EssilorLuxottica and Diesel announced today that they have signed an exclusive license agreement for the design, manufacture, and worldwide distribution of Diesel eyewear. The agreement will be effective immediately until December 31, 2029, with an automatic renewal option of an additional five years. The first collection under the agreement will be...
Nasdaq GlobeNewswire
18/06/2024
Actions to strengthen presence in North Africa : Congress & Surgeons trainings
Press release Ecully, June 18, 2024 – 6 p.m. Presentation of the KAPHORN system to 200 surgeons at the SOTCOT Congress in Hammamet The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, was represented at the 39th edition of theTunisian Orthopedic Society (SOTCOT)Congress, held from June 6 to 8 in Hammamet, Tunisia. Dr. Radwan Hilmi (Head of Orthopedics and Traumatology Department at Hôpital Nord Ouest,...
Nasdaq GlobeNewswire
18/06/2024
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024
AggregatedpresentationbydayandbymarketPurchases of own shares from June 10th to 14th 2024 Name of the IssuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1110/06/2024FR00102591505 000122,0351XPARIPSEN549300M6SGDPB4Z94P11...
Nasdaq GlobeNewswire
18/06/2024
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest…
Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy /Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen (ONIVYDE (ON) + 5-Fluorouracil (5FU) + Leucovorin (LV), a regimen that is already widely used for…
Nasdaq GlobeNewswire
18/06/2024
Oblique Therapeutics and the KTH Royal Institute of Technology (KTH) have…
About Oblique Therapeutics About Oblique Therapeutics Oblique Therapeutics is a biotechnology company that focuses on developing new therapeutic methods for treating severe illnesses, especially in the area of pain management and also for other conditions. The company uses pioneering technology and innovative research methods to discover and develop new drug candidates. About the KTH Royal Institute of Technology (KTH) KTH is the biggest technical university inSwedenand is one...
PR Newswire
18/06/2024
Healthcare BPO Market Anticipates USD 626.6 Billion by 2029 with 9.7% CAGR |…
Browse in-depth TOC on "Healthcare BPO Market" Browse in-depth TOC on "Healthcare BPO Market" 360 - Tables 60 - Figures350 - Pages Elevating Healthcare Efficiency: Driving Cost Reduction Through Strategic BPO Excellence The imperative to curb rising healthcare costs is a pivotal driver propelling growth within the healthcare BPO market. As healthcare expenditures surge, organizations face mounting pressure to optimize financial efficiencies. Outsourcing non-core...
PR Newswire
18/06/2024
Orthopedic Braces & Supports Market to Be Worth $4.64 Billion by 2031 -…
The growth of the orthopedic braces & supports market is driven by the increasing cases of bone fracture, the growing incidence of musculoskeletal disorders, and the growing availability & affordability of orthopedic support products. However, individuals' tendency to ignore smaller injuries and low awareness regarding bracing-mediated orthopedic treatments restrain the growth of this market. The growth of the orthopedic braces & supports market is driven by the increasing cases of…
PR Newswire
18/06/2024
Ceruvia Founder and CEO, Carey Turnbull, Featured in New Book "Psychedelic…
"Psychedelic Outlaws" chronicles the extraordinary journey of a group of individuals debilitated by cluster headaches, often referred to as 'suicide headaches' due to their extreme pain. Among these trailblazers is Bob Wold and the organization Clusterbusters®, dedicated advocates for those suffering from this debilitating condition. "Psychedelic Outlaws" chronicles the extraordinary journey of a group of individuals debilitated by cluster headaches, often referred to as…
PR Newswire
18/06/2024
Santhera's Shareholders Approve all Board Proposals at Today's Annual General…
Pratteln, Switzerland, June 18, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders approved all motions by the Board of Directors at the Annual General Meeting (AGM) held today in Pratteln, Switzerland, with a large majority. Participating shareholders represented a total of 4,535,785 shares or 35.9% of the Company's share capital. Approval of the 2023 Annual Report and discharge of corporate bodiesThe shareholders approved the Annual Report, the annual...
Nasdaq GlobeNewswire
18/06/2024
Novo Nordisk announces presentation of data from key semaglutide clinical trials…
FLOW kidney outcomes trial data evaluating efficacy and safety of once-weekly semaglutide 1.0 mg in people with type 2 diabetes 1 SELECT cardiovascular outcomes trial data evaluating efficacy and safety of once-weekly semaglutide 2.4 mg in people with obesity and established cardiovascular disease, without diabetes 2 STEP HFpEF trial programme data evaluating efficacy and safety of once-weekly semaglutide 2.4 mg in people with obesity-related heart failure with preserved ejection...
Nasdaq GlobeNewswire
18/06/2024
Zero Candida Announces First Intellectual Property in South Africa
The company is in the process of applying to the TSX Venture Exchange inCanadato list its shares at a proposed valuation of40 million Canadian dollars. Zero-Candida's technology is a game changer that has the potential to change the treatment of women and FemTech industry in the world. The first of its kind technology uses a controlled "Blue Light" to destroy the fungus at record speed and without side effects. The treatment is carried out by a tampon-like medical device which,...
PR Newswire
18/06/2024
Sidekick Health Expands Oncology and Women's Health Portfolio with Acquisition…
This acquisition brings with it PINK! Coach, the only permanently listed prescription digital therapeutic (PDT) for breast cancer within Germany's regulated nationwide DiGA (Digitale Gesundheitsanwendungen) formulary. PINK! Coach is a digital application developed to enhance health-related quality of life and health literacy, while also addressing the psychological, psychosomatic, and physical effects of breast cancer. To achieve a lasting improvement in quality of life and health, PINK! Coach…
PR Newswire
18/06/2024
Ability Biologics Announces the Closing of its US $18 Million Seed Funding…
"We're seeing a need for a new generation of antibodies and modalities as simply binding, blocking or agonizing a single receptor is not enough to achieve therapeutic impact," said Giles Day, Co-founder and CEO of Ability. "At Ability, our platform overlays multiple approaches in a single molecule, enhancing specificity and selectivity to develop potent therapeutics with broad therapeutic windows. To do so, our antibodies employ tried and tested IgG formats that enable easier…
PR Newswire
18/06/2024
Calliditas provides setanaxib patent update
"We are delighted that the product protection of setanaxib in the area of oncology is extended by way of this patent, and we look forward to expanding this to other geographies", said Renee Aguiar-Lucander, CEO. "We are delighted that the product protection of setanaxib in the area of oncology is extended by way of this patent, and we look forward to expanding this to other geographies", saidRenee Aguiar-Lucander, CEO. Calliditas read out positive topline results of its Phase…
PR Newswire
18/06/2024
Pie Medical Imaging announces enrollment completion of the FASTIII clinical…
Following the tremendous efforts of the principal investigator, Dr Joost Daemen (cardiologist at Thoraxcenter at the Erasmus University Medical Center, Rotterdam, The Netherlands), over 35 participating centers and ECRI (sponsor of the trial), the patient enrollment has concluded. Following the tremendous efforts of the principal investigator,DrJoost Daemen (cardiologist at Thoraxcenter at theErasmus UniversityMedical Center,Rotterdam, The Netherlands ), over 35 participating...
PR Newswire
18/06/2024
Medical devices industry statistics & trends: A multi-billion dollar opportunity…
Horizon Databook is the largest market research database with over one million data points across 20,000+ markets. The platform is first-in-class and is designed to service a full suite of market research clients. It is a one, five solution platform and includes the following: Horizon Databook is the largest market research database with over one million data points across 20,000+ markets. The platform is first-in-class and is designed to service a full suite of market research…
PR Newswire
18/06/2024
Future Health Index 2024 global report: Healthcare leaders turn to AI to address…
Healthcare leaders indicate automation is crucial in addressing staff shortages, but staff remain skeptical Interest in Generative AI grows, with majority of health leaders investing in, or planning to invest in AI technologies to help reduce delays in patient care Amsterdam, the Netherlands– Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the results of its Future Health Index 2024 report:Better care for more people. Launched...
Nasdaq GlobeNewswire
18/06/2024
Nexstim Plc: Disclosure of Major Holdings according to Chapter 9, Section 10 of…
Company announcement, Helsinki, 18 June 2024 at 11:30 AM (EEST) Nexstim Plc: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act Nexstim Plc (NXTMH:HEX) (”Nexstim” or ”Company”) has received a notification pursuant to chapter 9, section 5 of the Securities Market Act from Ossi Haapaniemi on 17 June 2024.The notification is based on the amendment to the Securities Market Act effective April 19, 2024, requiring shareholders to notify the...
Nasdaq GlobeNewswire
18/06/2024
Basecamp Research launches ZymCTRL a world-first, open source, generative AI…
LONDON, June 18, 2024 /PRNewswire/ -- Basecamp Research, a world leader in artificial intelligence (AI)-based design of proteins and other biological systems, in partnership with the Ferruz Laboratory at the Institute of Molecular Biology of Barcelona today announced the release of ZymCTRL ("enzyme control"), a ChatGPT-like tool that generates new sequences from scratch based on a user simply typing in an enzyme identification code, which specifies the desired activity. LONDON,June 18…
PR Newswire
18/06/2024
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed…
Advanz Pharma secures rights to commercialize Alvotech's biosimilar candidate for Eylea® in EuropeAdvanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure successful market registration, commercialization, and patient access REYKJAVIK, ICELAND and LONDON, UK (June 18, 2024)— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK...
Nasdaq GlobeNewswire
18/06/2024
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the…
Lung cancer is currently the most prevalent malignant tumor with the highest mortality rate in China. Small cell lung cancer (SCLC) is the most aggressive subtype of lung cancer, accounting for approximately 15%-20% of all lung cancer cases with characteristics including rapid progression, early metastasis and poor prognosis. SCLC is divided into limited-stage small cell lung cancer (LS-SCLC) and ES-SCLC. For patients with LS-SCLC, an objective response rate of approximately 90% and a...
Nasdaq GlobeNewswire
18/06/2024
AMSilk attends Pitti Filati for the first time to showcase biofabricated premium…
"Pitti Filati is the place to be for innovative yarns, as it attracts the most prestigious and influential brands and designers from around the world. Italy is also a key destination for us, as it is known for its high degree of excellence in fashion and textiles." commented Benoit Cugnet, Head of Fiber BU, AMSilk. "Pitti Filati is the place to be for innovative yarns, as it attracts the most prestigious and influential brands and designers from around the world.Italyis also a…
PR Newswire
18/06/2024
SpyBiotech Appoints Keith Dewedoff as new Chief Financial Officer
"I am proud to join the SpyBiotech team as the company continues to expand," said Keith Dewedoff. "Given the recently announced research collaboration with the University of Oxford and SpyBiotech's Phase I trial of its HCMV vaccine, this is a really exciting time to join the company." "I am proud to join the SpyBiotech team as the company continues to expand," saidKeith Dewedoff. "Given the recently announced research collaboration with theUniversity of…
PR Newswire
18/06/2024
Bioretec Appoints Frank Sarcone as Vice President of Sales for the US and a…
Frank Sarcone brings with him a wealth of experience and a remarkable track record in the medical device sector. With over 25 years of experience, Sarcone is recognized for his exceptional leadership, strategic acumen, and ability to build and mentor high-performing teams. His extensive background includes founding and leading successful orthopedic companies and developing national distribution channels that have significantly boosted sales and market presence. Frank Sarconebrings with him a...
PR Newswire
18/06/2024
Altri Comunicati
